Compounds > 7-monohydroxyethylrutoside
Page last updated: 2024-11-11

7-monohydroxyethylrutoside

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9852585
CHEMBL ID3527416
CHEBI ID134704
SCHEMBL ID435347
MeSH IDM0513512

Synonyms (45)

Synonym
monoxerutin [inn]
monoxerutinum [inn-latin]
2-(3,4-dihydroxyphenyl)-5-hydroxy-7-(2-hydroxyethoxy)-4-oxo-4h-chromen-3-yl-(6-o-(6-desoxy-alpha-l-mannopyranosyl)-beta-d-glucopyranosid)
rutilemone
relvene
mono-7-hydroxyethylrutoside
einecs 245-917-9
3,3',4',5-tetrahydroxy-7-(2-hydroxyethoxy)flavone 3-(6-o-(6-deoxy-alpha-l-mannopyranosyl)-beta-d-glucopyranoside)
monoxerutina [inn-spanish]
zyma sa
flavone, 3,3',4',5-tetrahydroxy-7-(2-hydroxyethoxy)-, 3-(6-o-(6-deoxy-alpha-l-mannopyranosyl)-beta-d-glucopyranoside)
beta-hydroxyethylrutosid
brn 4777354
varemoid
monoxerutin
monoxerutine [inn-french]
z 12007
o-(beta-hydroxyethyl)rutin
3,3',4',5-tetrahydroxy-7-(2-hydroxyethoxy)flavon-3-(6-o-(6-desoxy-alpha-l-mannopyranosyl)-beta-d-glucopyranosid)
o-(beta-hydroxyethyl)rutoside
monoxerutin (inn)
23869-24-1
D07179
7-monohydroxyethylrutoside
monoher
CHEBI:134704
monoxerutina
monoxerutinum
unii-ekf7043sbu
monoxerutine
ekf7043sbu ,
SCHEMBL435347
monoxerutin [mart.]
7-o-(.beta.-hydroxyethyl)rutoside
(beta-hydroxyethyl)rutoside, o-
monoxerutin [who-dd]
o-(.beta.-hydroxyethyl)rutoside, 7-
(.beta.-hydroxyethyl)rutoside, o-
CHEMBL3527416
DTXSID70905139
DB13764
Q6902068
2-pyrazin-2-yl-1,3-thiazole-4-carboxylicacid
2-(3,4-dihydroxyphenyl)-5-hydroxy-7-(2-hydroxyethoxy)-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one
AKOS040753131

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" From a study in human volunteers, we conclude that an intravenous dose of 1500 mg/m(2) of 7-monohydroxyethylrutoside is feasible and is safe to be investigated as protection against doxorubicin-induced cardiotoxicity."( Protectors against doxorubicin-induced cardiotoxicity: flavonoids.
Bast, A; den Hartog, GJ; Haenen, GR; Kaiserová, H; van der Vijgh, WJ, 2007)		0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
glycosideA glycosyl compound resulting from the attachment of a glycosyl group to a non-acyl group RO-, RS-, RSe-, etc. The bond between the glycosyl group and the non-acyl group is called a glycosidic bond. By extension, the terms N-glycosides and C-glycosides are used as class names for glycosylamines and for compounds having a glycosyl group attached to a hydrocarbyl group respectively. These terms are misnomers and should not be used. The preferred terms are glycosylamines and C-glycosyl compounds, respectively.
flavonoidsAny organic molecular entity whose stucture is based on derivatives of a phenyl-substituted 1-phenylpropane possessing a C15 or C16 skeleton, or such a structure which is condensed with a C6-C3 lignan precursors. The term is a 'superclass' comprising all members of the classes of flavonoid, isoflavonoid, neoflavonoid, chalcones, dihydrochalcones, aurones, pterocarpan, coumestans, rotenoid, flavonolignan, homoflavonoid and flavonoid oligomers. Originally restricted to natural products, the term is also applied to synthetic compounds related to them.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID1215525Drug metabolism in BALB/c mouse bile assessed as (2S,2'S,3S,3'S,4S,4'S,5R,5'R,6S,6'S)-6,6'-(4-(5-hydroxy-7-(2-hydroxyethoxy)-4-oxo-3-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)methyl)tetrah2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Identification of the metabolites of the antioxidant flavonoid 7-mono-O-(β-hydroxyethyl)-rutoside in mice.
AID1215521Drug metabolism in BALB/c mouse bile assessed as 2-(2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-3-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)methyl)tetrahydro-2H-pyran-2-yloxy)-4H-chromen-7-ylo2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Identification of the metabolites of the antioxidant flavonoid 7-mono-O-(β-hydroxyethyl)-rutoside in mice.
AID1215526Drug metabolism in BALB/c mouse bile assessed as 5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-(2-hydroxyethoxy)-3-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yloxy)-4H-chromen-4-one formation at 500 mg/kg, ip measured after 240 2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Identification of the metabolites of the antioxidant flavonoid 7-mono-O-(β-hydroxyethyl)-rutoside in mice.
AID1215534Half life in mouse heart2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Identification of the metabolites of the antioxidant flavonoid 7-mono-O-(β-hydroxyethyl)-rutoside in mice.
AID1215527Drug metabolism in BALB/c mouse bile assessed as (2S,3S,4S,5R,6S)-6-(5-(7-(carboxymethoxy)-5-hydroxy-4-oxo-3-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)methyl)tetrahydro-2H-pyran-2-yloxy)-42011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Identification of the metabolites of the antioxidant flavonoid 7-mono-O-(β-hydroxyethyl)-rutoside in mice.
AID1215519Retention time of the compound by LC-DAD-TOF-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Identification of the metabolites of the antioxidant flavonoid 7-mono-O-(β-hydroxyethyl)-rutoside in mice.
AID1215523Drug metabolism in BALB/c mouse bile assessed as 2-(5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-oxo-3-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)methyl)tetrahydro-2H-pyran-2-yloxy)-4H-chromen2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Identification of the metabolites of the antioxidant flavonoid 7-mono-O-(β-hydroxyethyl)-rutoside in mice.
AID1215518Drug level in BALB/c mouse bile treated with 7-mono-O-(beta-hydroxyethyl)-rutoside assessed as relative metabolite level at 500 mg/kg, ip measured after 60 mins by LC-DAD-TOF-MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Identification of the metabolites of the antioxidant flavonoid 7-mono-O-(β-hydroxyethyl)-rutoside in mice.
AID1215524Drug metabolism in BALB/c mouse bile assessed as (S)-4-amino-5-((R)-1-(carboxymethylamino)-3-(2,3-dihydroxy-6-(5-hydroxy-7-(2-hydroxyethoxy)-4-oxo-3-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-ylo2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Identification of the metabolites of the antioxidant flavonoid 7-mono-O-(β-hydroxyethyl)-rutoside in mice.
AID1215520Drug metabolism in BALB/c mouse bile assessed as (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(5-(5-hydroxy-7-(2-hydroxyethoxy)-4-oxo-3-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)methyl)tetrahydro-22011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Identification of the metabolites of the antioxidant flavonoid 7-mono-O-(β-hydroxyethyl)-rutoside in mice.
AID1215529Drug metabolism in BALB/c mouse bile assessed as 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-(2-hydroxyethoxy)-3-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yloxy)-4H-chromen-4-one formation at 500 mg/kg, ip measured after 240 mins b2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Identification of the metabolites of the antioxidant flavonoid 7-mono-O-(β-hydroxyethyl)-rutoside in mice.
AID1215533Half life in mouse plasma2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Identification of the metabolites of the antioxidant flavonoid 7-mono-O-(β-hydroxyethyl)-rutoside in mice.
AID1215522Drug metabolism in BALB/c mouse bile assessed as 5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-(2-hydroxyethoxy)-3-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)methyl)tetrahydro-2H-pyran-2-yloxy)2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Identification of the metabolites of the antioxidant flavonoid 7-mono-O-(β-hydroxyethyl)-rutoside in mice.
AID1215528Drug metabolism in BALB/c mouse bile assessed as (2S,3S,4S,5R,6S)-6-(5-(7-(carboxymethoxy)-5-hydroxy-4-oxo-3-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)methyl)tetrahydro-2H-pyran-2-yloxy)-42011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Identification of the metabolites of the antioxidant flavonoid 7-mono-O-(β-hydroxyethyl)-rutoside in mice.
AID1215530Drug metabolism in BALB/c mouse bile assessed as 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-(2-hydroxyethoxy)-3-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)methyl)tetrahydro-2H-pyran-2-yloxy)-4H-ch2011Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 39, Issue:5
Identification of the metabolites of the antioxidant flavonoid 7-mono-O-(β-hydroxyethyl)-rutoside in mice.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (33.33)29.6817
2010's10 (66.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.79

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.79 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.79)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (6.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (93.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
catechin
Catechin: An antioxidant flavonoid, occurring especially in woody plants as both (+)-catechin and (-)-epicatechin (cis) forms.. catechin : Members of the class of hydroxyflavan that have a flavan-3-ol skeleton and its substituted derivatives.. rac-catechin : A racemate comprising equimolar amounts of (+)- and (-)-catechin. (+)-catechin : The (+)-enantiomer of catechin and a polyphenolic antioxidant plant metabolite.		2.110catechinantioxidant;
plant metabolite
monocrotaline
Monocrotaline: A pyrrolizidine alkaloid and a toxic plant constituent that poisons livestock and humans through the ingestion of contaminated grains and other foods. The alkaloid causes pulmonary artery hypertension, right ventricular hypertrophy, and pathological changes in the pulmonary vasculature. Significant attenuation of the cardiopulmonary changes are noted after oral magnesium treatment.		2.0710pyrrolizidine alkaloid
daunorubicin
Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.		2.0410aminoglycoside antibiotic;
anthracycline;
p-quinones;
tetracenequinones		antineoplastic agent;
bacterial metabolite
hydroxyl radical
Hydroxyl Radical: The univalent radical OH. Hydroxyl radical is a potent oxidizing agent.		2.5120oxygen hydride;
oxygen radical;
reactive oxygen species
quercetin
[no description available]		2.46207-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
rutin
Hydroxyethylrutoside: Monohydroxyethyl derivative of rutin. Peripheral circulation stimulant used in treatment of venous disorders.		5.53151disaccharide derivative;
quercetin O-glucoside;
rutinoside;
tetrahydroxyflavone		antioxidant;
metabolite
interleukin-8
Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.		2.110
ascorbic acid
Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.		2.0510ascorbic acid;
vitamin C		coenzyme;
cofactor;
flour treatment agent;
food antioxidant;
food colour retention agent;
geroprotector;
plant metabolite;
skin lightening agent
ConditionIndicatedRelationship StrengthStudiesTrials
Fatty Liver, Nonalcoholic
[description not available]		02.1110
Non-alcoholic Fatty Liver Disease
Fatty liver finding without excessive ALCOHOL CONSUMPTION.		02.1110
Atypical Lipomatous Tumor
[description not available]		02.0610
Sarcoma, Epithelioid
[description not available]		02.0610
Liposarcoma
A malignant tumor derived from primitive or embryonal lipoblastic cells. It may be composed of well-differentiated fat cells or may be dedifferentiated: myxoid (LIPOSARCOMA, MYXOID), round-celled, or pleomorphic, usually in association with a rich network of capillaries. Recurrences are common and dedifferentiated liposarcomas metastasize to the lungs or serosal surfaces. (From Dorland, 27th ed; Stedman, 25th ed)		02.0610
Sarcoma
A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.		02.0610
Colorectal Cancer
[description not available]		02.0710
Hepatic Veno Occlusive Disease
[description not available]		02.0710
Hepatic Veno-Occlusive Disease
Liver disease that is caused by injuries to the ENDOTHELIAL CELLS of the vessels and subendothelial EDEMA, but not by THROMBOSIS. Extracellular matrix, rich in FIBRONECTINS, is usually deposited around the HEPATIC VEINS leading to venous outflow occlusion and sinusoidal obstruction.		02.0710
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		02.0710
Cardiac Diseases
[description not available]		03.8221
Weight Reduction
[description not available]		02.0310
Heart Diseases
Pathological conditions involving the HEART including its structural and functional abnormalities.		03.8221
Weight Loss
Decrease in existing BODY WEIGHT.		02.0310
Benign Neoplasms
[description not available]		03.4211
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.4211